Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 42 Records) |
| Query Trace: Fatigue and EGFR[original query] |
|---|
| Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted oncology 2015 Jun . Guetz Gaetan Des, Landre Thierry, Uzzan Bernard, Chouahnia Kader, Nicolas Patrick, Morere Jean-Franço |
| Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology 2015 1 26 (5): 998-1005. Wong A L, Soo R A, Tan D S, Lee S C, Lim J S, Marban P C, Kong L R, Lee Y J, Wang L Z, Thuya W L, Soong R, Yee M Q, Chin T M, Cordero M T, Asuncion B R, Pang B, Pervaiz S, Hirpara J L, Sinha A, Xu W W, Yuasa M, Tsunoda T, Motoyama M, Yamauchi T, Goh B |
| Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer research 2016 Sep 36 (9): 4951-4. Inomata Minehiko, Shimokawa Kazuki, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Yamada Toru, Miwa Toshiro, Hayashi Ryuji, Kashii Tatsuhiko, Matsui Shoko, Tobe Kazuyu |
| Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
| Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Oncotarget 2016 May . Zhang Minghui, Guo Hongsheng, Zhao Shu, Wang Yan, Yang Maopeng, Yu Jiawei, Yan Yubo, Wang Y |
| Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO open 2016 1 (6): e000086. Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro A R, Rachiglio A M, Lambiase M, Latiano T P, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli Vincenzo, Nasti Guglielmo, Nappi Anna, Botti Gerardo, Tatangelo F, Chicchinelli Nicoletta, Montrone Mirko, Sebastio Annamaria, Guarino Tiziana, Simone Gianni, Graziano Paolo, Chiarazzo Cinzia, Maggio GabrieleDi, Longhitano Laura, Manusia Mario, Cartenì Giacomo, Nappi Oscar, Micheli Pietro, Leo Luigi, Rossi Sabrina, Cassano Alessandra, Tommaselli Eugenio, Giordano Guido, Sponziello Francesco, Marino Antonella, Rinaldi Antonio, Romito Sante, Muda Andrea Onetti, Lorusso Vito, Leo Silvana, Barni Sandro, Grimaldi Giuseppe, Aieta Miche |
| Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. Internal medicine (Tokyo, Japan) 2017 8 56 (17): 2325-2328. Matsumoto Yoshiya, Kawaguchi Tomoya, Yamamoto Norio, Sawa Kenji, Yoshimoto Naoki, Suzumura Tomohiro, Watanabe Tetsuya, Mitsuoka Shigeki, Asai Kazuhisa, Kimura Tatsuo, Yoshimura Naruo, Kuwae Yuko, Hirata Kazu |
| Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung cancer (Amsterdam, Netherlands) 2017 11 113 51-58. Horn Leora, Gettinger Scott, Camidge D Ross, Smit Egbert F, Janjigian Yelena Y, Miller Vincent A, Pao William, Freiwald Matthias, Fan Jean, Wang Bushi, Chand Vikram K, Groen Harry J |
| Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. Investigational new drugs 2017 11 36 (4): 608-614. Tamiya Motohiro, Tamiya Akihiro, Shiroyama Takayuki, Takeoka Sawa, Naito Yujiro, Omachi Naoki, Kimura Yohei, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Okishio Kyoichi, Kawaguchi Tomoya, Atagi Shinji, Hirashima Tomono |
| A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
| Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. Clinical lung cancer 2017 1 18 (4): 388-395.e4. Labbé Catherine, Leung Yvonne, Silva Lemes João Gabriel, Stewart Erin, Brown Catherine, Cosio Andrea Perez, Doherty Mark, O'Kane Grainne M, Patel Devalben, Cheng Nicholas, Liang Mindy, Gill Gursharan, Rett Alexandra, Naik Hiten, Eng Lawson, Mittmann Nicole, Leighl Natasha B, Bradbury Penelope A, Shepherd Frances A, Xu Wei, Liu Geoffrey, Howell Dor |
| Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment. British journal of cancer 2018 8 119 (5): 558-564. de Langen Adrianus J, Jebbink M, Hashemi Sayed M S, Kuiper Justine L, de Bruin-Visser J, Monkhorst Kim, Thunnissen Erik, Smit Egbert |
| Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC cancer 2018 Dec 18 (1): 1231. Tsutani Yasuhiro, Miyata Yoshihiro, Masuda Takeshi, Fujitaka Kazunori, Doi Mihoko, Awaya Yoshikazu, Kuyama Shoichi, Kitaguchi Soichi, Ueda Kazuhiro, Hattori Noboru, Okada Morihi |
| The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis. Mathematical biosciences and engineering : MBE 2019 11 16 (6): 7921-7933. Wu Fa Zong, Song Jing Jing, Zhao Zhong Wei, Huang Xu Fang, Mao Jian Ting, Tu Jian Fei, Chen Min Jiang, Chen Wei Qian, Fang Shi Ji, Zheng Li Yun, Fan Xiao |
| Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. Oncology research 2019 Oct . Xu Jianping, Liu Xiaoyan, Yang Sheng, Shi Yuank |
| Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ?75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational lung cancer research 2020 7 9 (3): 459-470. Kozuki Toshiyuki, Nogami Naoyuki, Hataji Osamu, Tsunezuka Yoshio, Seki Nobuhiko, Harada Toshiyuki, Fujimoto Nobukazu, Bessho Akihiro, Takamura Kei, Takahashi Kazuhisa, Satouchi Miyako, Kato Terufumi, Shukuya Takehito, Yamashita Natsumi, Okamoto Hiroaki, Shinkai Tetsu, |
| Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung cancer (Amsterdam, Netherlands) 2020 10 150 62-69. Garcia-Campelo Rosario, Arrieta Oscar, Massuti Bartomeu, Rodriguez-Abreu Delvys, Granados Ana Laura Ortega, Majem Margarita, Vicente David, Lianes Pilar, Bosch-Barrera Joaquim, Insa Amelia, Dómine Manuel, Reguart Noemí, Guirado María, Sala María Ángeles, Vázquez-Estevez Sergio, Caro Reyes Bernabé, Drozdowskyj Ana, Verdú Ana, Karachaliou Niki, Molina-Vila Miguel Angel, Rosell Rafael, |
| Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020 Oct 1078155220964895. Celik Emir, Samanci Nilay Sengul, Karadag Mehmet, Demirci Nebi Serkan, Cikman Duygu Ilke, Derin Sumeyra, Bedir Sahin, Degerli Ezgi, Oruc Kerem, Oztas Nihan Senturk, Demirelli Fuat Hulu |
| Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO clinical and research reports 2021 9 2 (9): 100206. Park Keunchil, Tan Daniel Shao Weng, Su Wu-Chou, Cho Byoung Chul, Kim Sang-We, Lee Ki Hyeong, Wang Chin-Chou, Seto Takashi, Huang Dennis Chin-Lun, Jung Helen Hayoun, Hsu Ming-Chi, Bogenrieder Thomas, Lin Chia-C |
| Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. International journal of cancer 2021 9 150 (4): 636-644. Huang Yiqing, Soon Yu Yang, Aminkeng Folefac, Tay Sen Hee, Ang Yvonne, Kee Adrian C L, Goh Boon Cher, Wong Alvin S C, Soo Ross |
| Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Jun . Akamatsu Hiroaki, Murakami Haruyasu, Harada Hideyuki, Shimizu Junichi, Hayashi Hidetoshi, Daga Haruko, Hasegawa Yoshikazu, Kim Young Hak, Kato Terufumi, Tokunaga Shoji, Nishimura Yasumasa, Yamamoto Nobuyuki, Nakagawa Kazuhi |
| Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted oncology 2021 5 16 (3): 339-355. Yoh Kiyotaka, Hirashima Tomonori, Saka Hideo, Kurata Takayasu, Ohe Yuichiro, Hida Toyoaki, Mellemgaard Anders, Verheijen Remy B, Ou Xiaoling, Ahmed Ghada F, Hayama Manabu, Sugibayashi Ko, Oxnard Geoffrey |
| Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pacific journal of cancer prevention : APJCP 2021 May 22 (5): 1581-1590. Vu Thanh Ha, Nguyen Hoa Thi Thai, Dao Linh Khanh, Duong Chi Khanh, Nguyen Cao Van, Doan Tuyet Thi, Nguyen Hang Thi Thuy, Hoang Hung Huy, Dinh Dung Khac, Le Giang Vinh, Vu Thanh Thi, Truong Minh Cong, Nguyen Long Tha |
| Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO precision oncology 2021 5 1 . McCoach Caroline E, Yu Aiming, Gandara David R, Riess Jonathan W, Vang Daniel P, Li Tiahong, Lara Primo N, Gubens Matthew, Lara Frances, Mack Philip C, Beckett Laurel A, Kelly Kar |
| A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer chemotherapy and pharmacology 2021 11 89 (1): 105-115. Padda Sukhmani K, Reckamp Karen L, Koczywas Marianna, Neal Joel W, Kawashima Jun, Kong Shengchun, Huang Daniel B, Kowalski Mark, Wakelee Heather |
| FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 9 29 (3): 508-512. Duke Elizabeth S, Stapleford Liza, Drezner Nicole, Amatya Anup K, Mishra-Kalyani Pallavi S, Shen Yuan-Li, Maxfield Kimberly, Zirkelbach Jeanne Fourie, Bi Youwei, Liu Jiang, Zhang Xinyuan, Wang Hezhen, Yang Yuching, Zheng Nan, Reece Kelie, Wearne Emily, Glen Jacqueline J, Ojofeitimi Idara, Scepura Barbara, Nair Abhilasha, Bikkavilli Rama Kamesh, Ghosh Soma, Philip Reena, Pazdur Richard, Beaver Julia A, Singh Harpreet, Donoghue Mart |
| Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer. ERJ open research 2022 10 8 (4): . Gijtenbeek Rolof G P, van der Noort Vincent, Aerts Joachim G J V, Staal-van den Brekel Jeske A, Smit Egbert F, Krouwels Frans H, Wilschut Frank A, Hiltermann T Jeroen N, Timens Wim, Schuuring Ed, Janssen Joost D J, Goosens Martijn, van den Berg Paul M, de Langen A Joop, Stigt Jos A, van den Borne Ben E E M, Groen Harry J M, van Geffen Wouter H, van der Wekken Anthonie |
| The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study. Cancer medicine 2023 9 . Shuyang Zhang, Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wa |
| Low?dose anlotinib combined with EGFR?TKI can be used as an alternative for EGFR?TKI?resistant non?small cell lung cancer in elderly patients. Oncology letters 2023 7 26 (2): 323. Yi Chen, Nanyuan Jiang, Xiao Liang, Nan Chen, Yun Chen, Chen Zhang, Junfeng Shi, Renhua G |
| RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: